Immersive virtual reality simulation for technical skills acquisition in pneumothorax management and chest tube insertion: A randomized controlled trial among surgery interns.

InjuryJun 18, 2026 (epub)
Clinical ResearchGeneral SurgeryCardiothoracic Surgery

Sebastian Leon, Armaun D Rouhi, Dheeraj Baji et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated the effectiveness of immersive virtual reality (IVR) simulation for teaching pneumothorax management and chest tube insertion to first-year surgery residents. The IVR group achieved a mean OSATS score of 39.8 compared to 36.7 in the control group, with a statistically significant p-value of 0.008, indicating superior technical skills acquisition.

Key findings

  • IVR group had a mean OSATS score of 39.8 vs 36.7 in the control group, p = 0.008.
  • Higher scores in rib blunt dissection: 4.14 vs 3.79, p = 0.035.
  • IVR group required less tutor assistance: 4.00 vs 3.33, p = 0.008.
  • Total cost for five HMDs was $1749.95.

Why it matters

The study highlights the potential of immersive virtual reality as an effective training tool in surgical education, which may enhance the technical skills of residents and improve patient outcomes in procedures like chest tube insertion.

Source

PubMed · PMID 42373377

Published in Injury. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in General Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.